1547 related articles for article (PubMed ID: 29169110)
1. Disorder of gut amino acids metabolism during CKD progression is related with gut microbiota dysbiosis and metagenome change.
Liu Y; Li J; Yu J; Wang Y; Lu J; Shang EX; Zhu Z; Guo J; Duan J
J Pharm Biomed Anal; 2018 Feb; 149():425-435. PubMed ID: 29169110
[TBL] [Abstract][Full Text] [Related]
2. Alterations to the Gut Microbiota and Their Correlation With Inflammatory Factors in Chronic Kidney Disease.
Li F; Wang M; Wang J; Li R; Zhang Y
Front Cell Infect Microbiol; 2019; 9():206. PubMed ID: 31245306
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach.
Mishima E; Fukuda S; Mukawa C; Yuri A; Kanemitsu Y; Matsumoto Y; Akiyama Y; Fukuda NN; Tsukamoto H; Asaji K; Shima H; Kikuchi K; Suzuki C; Suzuki T; Tomioka Y; Soga T; Ito S; Abe T
Kidney Int; 2017 Sep; 92(3):634-645. PubMed ID: 28396122
[TBL] [Abstract][Full Text] [Related]
4. Synbiotics Alleviate the Gut Indole Load and Dysbiosis in Chronic Kidney Disease.
Yang CY; Chen TW; Lu WL; Liang SS; Huang HD; Tseng CP; Tarng DC
Cells; 2021 Jan; 10(1):. PubMed ID: 33435396
[TBL] [Abstract][Full Text] [Related]
5. Fecal metabonomics combined with 16S rRNA gene sequencing to analyze the changes of gut microbiota in rats with kidney-yang deficiency syndrome and the intervention effect of You-gui pill.
Chen R; Wang J; Zhan R; Zhang L; Wang X
J Ethnopharmacol; 2019 Nov; 244():112139. PubMed ID: 31401318
[TBL] [Abstract][Full Text] [Related]
6. The fecal microbiome and serum concentrations of indoxyl sulfate and p-cresol sulfate in cats with chronic kidney disease.
Summers SC; Quimby JM; Isaiah A; Suchodolski JS; Lunghofer PJ; Gustafson DL
J Vet Intern Med; 2019 Mar; 33(2):662-669. PubMed ID: 30561098
[TBL] [Abstract][Full Text] [Related]
7. Characterizing the gut microbiota in patients with chronic kidney disease.
Hu X; Ouyang S; Xie Y; Gong Z; Du J
Postgrad Med; 2020 Aug; 132(6):495-505. PubMed ID: 32241215
[No Abstract] [Full Text] [Related]
8. The Accumulation of Gut Microbiome-derived Indoxyl Sulfate and P-Cresyl Sulfate in Patients With End-stage Renal Disease.
Lin X; Liang W; Li L; Xiong Q; He S; Zhao J; Guo X; Xiang S; Zhang P; Wang H; Ying C; Yao Y; Zuo X
J Ren Nutr; 2022 Sep; 32(5):578-586. PubMed ID: 34736844
[TBL] [Abstract][Full Text] [Related]
9. Uremic Toxin-Producing Gut Microbiota in Rats with Chronic Kidney Disease.
Kikuchi M; Ueno M; Itoh Y; Suda W; Hattori M
Nephron; 2017; 135(1):51-60. PubMed ID: 27701177
[TBL] [Abstract][Full Text] [Related]
10. Gancao-Gansui combination impacts gut microbiota diversity and related metabolic functions.
Yu J; Guo J; Tao W; Liu P; Shang E; Zhu Z; Fan X; Shen J; Hua Y; Zhu KY; Tang Y; Duan JA
J Ethnopharmacol; 2018 Mar; 214():71-82. PubMed ID: 29198875
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.
Gryp T; De Paepe K; Vanholder R; Kerckhof FM; Van Biesen W; Van de Wiele T; Verbeke F; Speeckaert M; Joossens M; Couttenye MM; Vaneechoutte M; Glorieux G
Kidney Int; 2020 Jun; 97(6):1230-1242. PubMed ID: 32317112
[TBL] [Abstract][Full Text] [Related]
12. Microbiome perturbation by oral vancomycin reduces plasma concentration of two gut-derived uremic solutes, indoxyl sulfate and p-cresyl sulfate, in end-stage renal disease.
Nazzal L; Roberts J; Singh P; Jhawar S; Matalon A; Gao Z; Holzman R; Liebes L; Blaser MJ; Lowenstein J
Nephrol Dial Transplant; 2017 Nov; 32(11):1809-1817. PubMed ID: 28379433
[TBL] [Abstract][Full Text] [Related]
13. Effects of the oral adsorbent AST-120 on fecal p-cresol and indole levels and on the gut microbiota composition.
Sato E; Hosomi K; Sekimoto A; Mishima E; Oe Y; Saigusa D; Ito S; Abe T; Sato H; Kunisawa J; Niwa T; Takahashi N
Biochem Biophys Res Commun; 2020 May; 525(3):773-779. PubMed ID: 32147096
[TBL] [Abstract][Full Text] [Related]
14. Isolation and Quantification of Uremic Toxin Precursor-Generating Gut Bacteria in Chronic Kidney Disease Patients.
Gryp T; Huys GRB; Joossens M; Van Biesen W; Glorieux G; Vaneechoutte M
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183306
[TBL] [Abstract][Full Text] [Related]
15. p-Cresyl Sulfate.
Gryp T; Vanholder R; Vaneechoutte M; Glorieux G
Toxins (Basel); 2017 Jan; 9(2):. PubMed ID: 28146081
[TBL] [Abstract][Full Text] [Related]
16. Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial.
Rossi M; Johnson DW; Morrison M; Pascoe EM; Coombes JS; Forbes JM; Szeto CC; McWhinney BC; Ungerer JP; Campbell KL
Clin J Am Soc Nephrol; 2016 Feb; 11(2):223-31. PubMed ID: 26772193
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Bennis Y; Cluet Y; Titeca-Beauport D; El Esper N; Ureña P; Bodeau S; Combe C; Dussol B; Fouque D; Choukroun G; Liabeuf S
Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31109001
[TBL] [Abstract][Full Text] [Related]
18. Does Low-Protein Diet Influence the Uremic Toxin Serum Levels From the Gut Microbiota in Nondialysis Chronic Kidney Disease Patients?
Black AP; Anjos JS; Cardozo L; Carmo FL; Dolenga CJ; Nakao LS; de Carvalho Ferreira D; Rosado A; Carraro Eduardo JC; Mafra D
J Ren Nutr; 2018 May; 28(3):208-214. PubMed ID: 29439931
[TBL] [Abstract][Full Text] [Related]
19. Gut Microbiota as Diagnostic Tools for Mirroring Disease Progression and Circulating Nephrotoxin Levels in Chronic Kidney Disease: Discovery and Validation Study.
Wu IW; Lin CY; Chang LC; Lee CC; Chiu CY; Hsu HJ; Sun CY; Chen YC; Kuo YL; Yang CW; Gao SS; Hsieh WP; Chung WH; Lai HC; Su SC
Int J Biol Sci; 2020; 16(3):420-434. PubMed ID: 32015679
[TBL] [Abstract][Full Text] [Related]
20. Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients.
Xu KY; Xia GH; Lu JQ; Chen MX; Zhen X; Wang S; You C; Nie J; Zhou HW; Yin J
Sci Rep; 2017 May; 7(1):1445. PubMed ID: 28469156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
